Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-08-01

FDA Approved: AVALIDE — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for AVALIDE (irbesartan and hydrochlorothiazide) submitted by Sanofi-Aventis U.S. LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AVALIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)

Snippet

SUPPL AP for AVALIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)